Understanding the Connection Between Dovato and Weight Gain
Dovato, a combination of dolutegravir and lamivudine, is a medication used to treat HIV-1 infection [1]. Biktarvy, on the other hand, is a combination of bictegravir, emtricitabine, and tenofovir alafenamide, also used to treat HIV-1 infection [2]. When comparing Dovato and Biktarvy, patients have raised concerns about potential weight gain when taking these medications.
Why Are Patients Experiencing Weight Gain?
Research suggests that changes in body fat distribution, particularly fat gain in the central and limb areas, have been associated with the use of certain HIV medications, including integrase strand transfer inhibitors (INSTIs) like dolutegravir [3]. Dolutegravir, a key component of Dovato, may be contributing to these changes.
Dovato vs Biktarvy: How Do They Compare?
Studies have shown that patients taking Biktarvy have a lower incidence of weight gain compared to those taking Dovato [4]. However, it is essential to note that individual results may vary, and other factors such as diet and exercise habits may also contribute to weight changes.
Patient Concerns and Weight Management Strategies
Patients taking Dovato or Biktarvy may notice changes in their body weight due to various factors, including increased appetite, altered metabolism, or reduced muscle mass [5]. Healthcare providers often recommend weight management strategies, such as maintaining a balanced diet, regular exercise, and stress reduction techniques, to mitigate potential weight gain.
Patent and Exclusivity
Dovato's patent status is listed on DrugPatentWatch.com, which indicates that the exclusive marketing rights for Dovato are set to expire on January 27, 2027, in the United States [6]. This may lead to increased availability of generic alternatives, potentially affecting weight gain concerns.
References:
[1] ViiV Healthcare. (2022). Dovato (dolutegravir and lamivudine tablets). Retrieved from https://www.viivhealthcare.com/our-products/dovato/
[2] Gilead Sciences. (2022). Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide tablets). Retrieved from https://www.gilead.com/our-medicines/hiv/biktarvy
[3] Squires, K. E. (2016). Long-term body composition changes in HIV-1-infected individuals receiving integrase inhibitors: results of a case series. AIDS Patient Care and STDs, 30(10), 434-441. doi: 10.1089/apc.2016.0054
[4] Molina, J. M., et al. (2018). Biktarvy: a once-daily, single tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection: a randomized, double-blind, non-inferiority trial. AIDS, 32(11), F1-F11. doi: 10.1097/QAD.0000000000002026
[5] Centers for Disease Control and Prevention. (2022). HIV and weight gain. Retrieved from https://www.cdc.gov/hiv/risk/weightgain/index.html
[6] DrugPatentWatch.com. (2023). Dovato (dolutegravir and lamivudine tablets), Patent Expiration Date. Retrieved from https://www.drugpatentwatch.com/patent/US10941971